According to results of a phase 3 study, SoluMatrix indomethacin exhibited opioid-sparing effects in patients with acute postoperative pain following bunionectomy surgery.

• Placebo-controlled phase 3 study evaluated the opioid-sparing effects of SoluMatrix indomethacin in patients with acute moderate-to-severe pain after undergoing bunionectomy surgery
• 462 patients were randomized to receive 40mg SoluMatrix indomethacin three times daily, 40mg SoluMatrix indomethacin twice daily, 20mg SoluMatrix indomethacin three times daily, 200mg celecoxib twice daily following a 400-mg loading dose, or placebo
• Evaluated the proportion of patients that required rescue medication, the amount of rescue medication required on Days 1 and 2 after administration of the initial dose of study medication, and the time to first rescue medication use

• On day 1, opioid-containing rescue therapy was required by fewer patients in the 20- and 40-mg SoluMatrix indomethacin three times daily treatment groups vs patients in the placebo group (P0.034)
• On day 2, rescue medication use was required by fewer patients in all active treatment groups vs placebo (P<0.001)
• All active treatment groups required fewer rescue medication tablets compared to placebo on both day 1 and day 2 (P<0.001)
• Common adverse events: nauseas, postprocedural edema, headache